Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs)
has proven its feasibility and therapeutic potential in the treatment of malignant tumors. To …

The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …

T cells in tumors—the so-called tumor infiltrating lymphocytes (TIL) have been studied
intensively over the past years. Compelling evidence point to a clinical relevance for high …

Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) plays a key role in restraining the
adaptive immune response of T-cells towards a variety of antigens including tumor …

The tumor microenvironment mediates induction of the immunosuppressive programmed
cell death-1 (PD-1) pathway, and targeted interventions against this pathway can help …

4-1BB agonist antibody treatment induces a population of KLRG1+ T cells that infiltrate
melanoma tumors. We investigated the origin and function of these cells, as well as their …

Purpose Mounting evidence suggests that tumor-infiltrating immune cells have prognostic
value for patients with solid organ malignancies. Our aim was to investigate the prognostic …

There is an urgent need for improved therapy for advanced ovarian carcinoma, which may
be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a …

In 2011, the US Food and Drug Administration approved the first new therapy for melanoma
in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks …

Objective Radiotherapy affects antitumor immune responses; therefore, it is important to
study radiation effects on various compartments of the immune system. Here we report …